Get the app!
Back to Trades
Sell4

Travere Therapeutics, Inc.

TVTX

Total Value
$2.6M
Net $2.6M sold
Sales
$2.6M
3 transactions

Company Information

Ticker Symbol
TVTX
CIK
0001438533

Insider Information

Role
Insider
Location
SAN DIEGO, CA

Filing Details

Filing Date
Apr 15, 2026
Transaction Date
Apr 13, 2026
Accession Number
0001763494-26-000005
Form Type
4
Net Trading Amount
-$2.6M

Non-Derivative Transactions

DateSecuritySharesPriceTypeValue
Apr 13, 2026Common Stock64,000Grant/Award
Apr 15, 2026Common Stock56,815$41.01Sale$2.3M
Apr 15, 2026Common Stock7,165$41.75Sale$299.1K
Apr 15, 2026Common Stock20$42.66Sale$853

Footnotes

  1. (F1)On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.
  2. (F2)This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
  3. (F3)The weighted average sale price for the transaction reported was $41.01, and the range of prices were between $40.51 and $41.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  4. (F4)The weighted average sale price for the transaction reported was $41.75, and the range of prices were between $41.52 and $42.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC Filing

View on SEC Daily

View the complete filing document on SEC Daily.